Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C481-mutated BTK with equal low nM potency.
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study / Cohen, Jonathon B; Shah, Nirav N; Alencar, Alvaro J; Gerson, James N; Patel, Manish R; Fakhri, Bita; Jurczak, Wojciech; Tan, Xuan Ni; Lewis, Katharine L; Fenske, Timothy; Coombs, Catherine C; Flinn, Ian W; Lewis, David J; Gouill, Steven Le; Palomba, M Lia; Woyach, Jennifer A; Pagel, John M; Lamanna, Nicole; Barve, Minal A; Ghia, Paolo; Eyre, Toby A; Zinzani, Pier Luigi; Ujjani, Chaitra S; Koh, Youngil; Izutsu, Koji; Lech-Maranda, Ewa; Tam, Constantine S; Sundaram, Suchitra; Yin, Ming; Nair, Binoj; Tsai, Donald E; Balbas, Minna; Mato, Anthony R; Cheah, Chan Y; Wang, Michael L. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2669. - 22 Suppl 2:(2022), pp. S394-S395. [10.1016/S2152-2650(22)01569-5]
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Ghia, Paolo
;
2022-01-01
Abstract
Covalent BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL), but most patients will require additional treatment. Pirtobrutinib is a highly selective, non-covalent (reversible) BTKi that inhibits both wild-type and C481-mutated BTK with equal low nM potency.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
